 PDF 30KB - Bone Histology demonstration of the utility of the CAP/CIP Ratio to accurately discriminate Adynamic Bone Disease from High Bone Turnover Disease with the similar 1-84 PTH Value |
PDF 26KB - Bone Histology from 7 ESRD Patients confirmed that no patient with Hyperparathyroidism had a CAP/CIP Ratio of < 1.5 |
PDF 29KB - Calcium x Phosphate Control - The Benefit of the Scantibodies CAP/CIP Ratio |
| PDF 24KB - Diagnostic Probablility Guidline for the CAP/CIP Ratio |
PDF 39KB - Treatment Protocol using Doxercalciferol (Hectorol®) and Intact PTH and the CAP/CIP Ratio |
PDF 38KB - Treatment Protocol using Doxercalciferol (Hectorol®) and CAP and the CAP/CIP Ratio |
| PDF 21KB - Comparison between the Scantibodies Total Intact PTH Assay and the Nichols Advantage Intact PTH Assay |
PDF 31KB - The Relationship between CAP (1-84 PTH) and Serum Calcium |
PDF 29KB - The Relationship between the CAP/CIP Ratio and Serum Calcium |
| PDF 26KB - Unexplained Increase in Parathyroidectomies in the U. S. since 1998 |
PDF 24KB - The difference in the Scantibodies CAP/CIP Ratios between Stage 1 and Stage 2 pre-ESRD patients |
PDF 27KB - The Scantibodies CAP/CIP Ratio Identifies 40% more Adynamic Bone Disease Patients than the Scantibodies Total Intact PTH, CAP alone or Nichols Bio-Intact PTH Assays |
|
PDF 35KB - New PTH Assays - Do they really make a diagnostic difference? |
|
